

At page 19, line 10, please delete "zolendronate" and replace with  
-- zoledronate --.

At page 22, line 14, please delete "omeprazole" and replace with --omeprazole --.

At page 33, line 33, please delete "zolendronate" and replace with  
-- zoledronate --.

At page 35, line 1, please delete "zolendronate" and replace with -- zoledronate --.

Insert the Abstract of the Invention as the last page, page 41, of the specification:

-- ABSTRACT OF THE INVENTION

Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein. The compounds are bisphosphonates selected from the group consisting of alendronate, cimadronate, clodronate, tiludronate, [etidronate]etidronate, ibandronate, risedronate, piridronate, pamidronate, [zolendronate]zoledronate, optionally in combination with a histamine H2 antagonist. --

IN THE CLAIMS:

Please cancel Claims 1-52 without prejudice.

Please add the following new Claim 53.

-- 53. A pharmaceutical composition comprising about 140 mg, on an alendronic acid active basis, of a bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof. --

REMARKS

Claims 1-52 have been cancelled without prejudice, and upon entry of this amendment, Claim 53 will be pending.

In the specification, the section "CROSS REFERENCE TO RELATED APPLICATIONS" has been amended to provide the priority of the present application. The specification has also been amended to correct minor typographical errors.


No new matter is being added to the above-captioned application by the submission of the Abstract of the Invention, nor by the correction of minor typographical errors in the spelling thereof, because it is substantially identical to that in the priority document PCT/US98/14796. Furthermore, new Claim 53 is *identical* to original Claim 31.

For the Examiner's convenience, a separate sheet for the now *amended* Abstract of the Invention (page 41) is enclosed for inclusion with the specification of the U.S. National Phase Application being filed.

In summary, Applicants respectfully request examination and passage to issue of the present claim.

Respectfully submitted,

By



Anthony D. Sabatelli, Reg. No. 34,714  
Attorney for Applicants

/agb  
Enclosure

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
Tel: (732) 594-1935

December 13, 1999

662727 4E84460